Q-Score: development of a new metric for continuous glucose monitoring that enables stratification of antihyperglycaemic therapies
Open Access
- 1 May 2015
- journal article
- research article
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 15 (1) , 22
Abstract
Continuous glucose monitoring (CGM) has revolutionised diabetes management. CGM enables complete visualisation of the glucose profile, and the uncovering of metabolic ‘weak points’. A standardised procedure to evaluate the complex data acquired by CGM, and to create patient-tailored recommendations has not yet been developed. We aimed to develop a new patient-tailored approach for the routine clinical evaluation of CGM profiles. We developed a metric allowing screening for profiles that require therapeutic action and a method to identify the individual CGM parameters with improvement potential. Fifteen parameters frequently used to assess CGM profiles were calculated for 1,562 historic CGM profiles from subjects with type 1 or type 2 diabetes. Factor analysis and varimax rotation was performed to identify factors that accounted for the quality of the profiles. We identified five primary factors that determined CGM profiles (central tendency, hyperglycaemia, hypoglycaemia, intra- and inter-daily variations). One parameter from each factor was selected for constructing the formula for the screening metric, (the ‘Q-Score’). To derive Q-Score classifications, three diabetes specialists independently categorised 766 CGM profiles into groups of ‘very good’, ‘good’, ‘satisfactory’, ‘fair’, and ‘poor’ metabolic control. The Q-Score was then calculated for all profiles, and limits were defined based on the categorised groups (<4.0, very good; 4.0–5.9, good; 6.0–8.4, satisfactory; 8.5–11.9, fair; and ≥12.0, poor). Q-Scores increased significantly (P <0.01) with increasing antihyperglycaemic therapy complexity. Accordingly, the percentage of fair and poor profiles was higher in insulin-treated compared with diet-treated subjects (58.4% vs. 9.3%). In total, 90% of profiles categorised as fair or poor had at least three parameters that could potentially be optimised. The improvement potential of those parameters can be categorised as ‘low’, ‘moderate’ and ‘high’. The Q-Score is a new metric suitable to screen for CGM profiles that require therapeutic action. Moreover, because single components of the Q-Score formula respond to individual weak points in glycaemic control, parameters with improvement potential can be identified and used as targets for optimising patient-tailored therapies.Keywords
This publication has 38 references indexed in Scilit:
- How can we monitor glycaemic variability in the clinical setting?Diabetes, Obesity and Metabolism, 2013
- Use of an Automated Decision Support Tool Optimizes Clinicians’ Ability to Interpret and Appropriately Respond to Structured Self-Monitoring of Blood Glucose DataDiabetes Care, 2012
- Translating Glucose Variability Metrics into the Clinic via C ontinuous G lucose M onitoring: A G raphical U ser I nterface for D iabetes E valuation (CGM-GUIDE © )Diabetes Technology & Therapeutics, 2011
- Persistence of Individual Variations in Glycated HemoglobinDiabetes Care, 2011
- Effectiveness of Continuous Glucose Monitoring in a Clinical Care EnvironmentDiabetes Care, 2009
- Factors Predictive of Use and of Benefit From Continuous Glucose Monitoring in Type 1 DiabetesDiabetes Care, 2009
- Statistical Tools to Analyze Continuous Glucose Monitor DataDiabetes Technology & Therapeutics, 2009
- Outpatient Assessment of Karlsburg Diabetes Management System–Based Decision SupportDiabetes Care, 2007
- Day-to-day variation of continuously monitored glycaemia: A further measure of diabetic instabilityDiabetologia, 1972
- Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.Psychological Bulletin, 1968